{"id":"NCT05172050","sponsor":"Domp√© Farmaceutici S.p.A","briefTitle":"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.","officialTitle":"Multicenter, Adaptive, Randomized, Placebo-controlled, Double Blind, Parallel-group Phase 2/3 Trial, to Study Efficacy and Safety of Two Doses of Raloxifene in Adult Paucisymptomatic COVID-19 Patients.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-01-22","primaryCompletion":"2021-06-12","completion":"2021-06-12","firstPosted":"2021-12-29","resultsPosted":"2023-12-14","lastUpdate":"2023-12-26"},"enrollment":61,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["SARS CoV 2 Infection"],"interventions":[{"type":"DRUG","name":"Raloxifene","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":["control"]}],"arms":[{"label":"Group 1: Raloxifene 60 mg","type":"EXPERIMENTAL"},{"label":"Group 2: Raloxifene 120 mg","type":"EXPERIMENTAL"},{"label":"Group 3: Placebo.","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.\n\nPrimary objectives:\n\n* Evaluation of the effectiveness of therapy in reducing the proportion of subjects who still have viruses in the upper airways after 7 days of therapy\n* Evaluation of the effectiveness of therapy in reducing the proportion of subjects who requires supplemental oxygen therapy and/or mechanical ventilation within 14 days of starting therapy\n\nSecondary objectives:\n\n* Evaluation of the effectiveness of therapy in reducing the proportion of subjects who still have viruses in the upper airways after 14 and 28 days of therapy\n* Evaluation of the effectiveness of therapy in reducing the proportion of subject patients who requires supplemental oxygen therapy and/or mechanical ventilation within 7 or 28 days of starting therapy\n* 7, 14 and 28 days drug safety and tolerability profile\n* Assessment of body temperature, blood and biochemical parameters between T0 and T28","primaryOutcome":{"measure":"Number of Participants With Undetectable SARS-CoV-2 at PCR at Day 7 After Randomization in the FAS","timeFrame":"At Day 7","effectByArm":[{"arm":"Raloxifene 60 mg","deltaMin":7,"sd":null},{"arm":"Raloxifene 120 mg","deltaMin":4,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0109"},{"comp":"OG001 vs OG002","p":"0.0673"},{"comp":"OG000 vs OG002","p":"0.0061"},{"comp":"OG001 vs OG002","p":"0.0567"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["France","Italy","Spain"]},"refs":{"pmids":["35582123"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":22},"commonTop":["Abdominal pain","Gastric disorder","Gastrointestinal disorder","Nausea","Vessel puncture site bruise"]}}